An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain

Inclusion Criteria: * Subject is informed and given ample time and opportunity to think about her/his participation in this extension trial and has given her/his written informed consent * Subject met all inclusion criteria defined in the SP611 trial with SPM927 at the time of enrollment into trial SP611 * Subject has successfully completed trial SP611 and, in the investigator's opinion, would benefit from long-term administration of SPM927 * Subject is willing and able to comply with all trial requirements, including the ability to complete trial questionnaires Exclusion Criteria: * Subject previously participated in this trial * Subject has participated in another trial of an investigational drug within the last 3 months (excluding trial SP611) or is currently participating in another trial of an investigational drug * Subject has had prior therapy with a Nonsteroidal Anti-inflammatory Drug (NSAID) or Anti-epileptic Drug (AED) within 28 days prior to the Eligibility Visit * Subject has evidence or history of significant Cardiovascular Disease within 12 months prior to the Eligibility Visit * Subject has laboratory values, which are outside the normal range and judged by the Investigator to be clinically significant * Subject has abnormal Renal or Hepatic function * Subject has a history of Malignancies with the exception of subjects with a documented disease-free interval of 5 years or more * Subject has a history of chronic alcohol or drug abuse within the last 12 months * Subject has any medical or psychiatric condition which, in the opinion of the Investigator, could jeopardize or compromise the subject's ability to participate in this continuation trial * Subject with a known history of severe Anaphylactic Reaction and/or serious or life threatening Blood Dyscrasias